The MUMPS: McGill University Medical Podcast Series-logo

The MUMPS: McGill University Medical Podcast Series

Science Podcasts >

Hey there, and welcome to The MUMPS: The McGill University Medical Podcast Series! This is a podcast geared towards aspiring, training or practicing health care professionals who are looking to keep up to date with the latest medical research going on at McGill and its affiliated institutions. Tune in bi-monthly as your hosts Russ and Eric chat with basic science and clinical researchers behind some of McGill University's most current, influential and thought-provoking medical research.

Hey there, and welcome to The MUMPS: The McGill University Medical Podcast Series! This is a podcast geared towards aspiring, training or practicing health care professionals who are looking to keep up to date with the latest medical research going on at McGill and its affiliated institutions. Tune in bi-monthly as your hosts Russ and Eric chat with basic science and clinical researchers behind some of McGill University's most current, influential and thought-provoking medical research.
More Information

Location:

Canada

Description:

Hey there, and welcome to The MUMPS: The McGill University Medical Podcast Series! This is a podcast geared towards aspiring, training or practicing health care professionals who are looking to keep up to date with the latest medical research going on at McGill and its affiliated institutions. Tune in bi-monthly as your hosts Russ and Eric chat with basic science and clinical researchers behind some of McGill University's most current, influential and thought-provoking medical research.

Language:

English

Contact:

4384925671


Episodes

Episode 4 - Dr. Richard Menzies and Dr. Jonathan Campbell - 4 months of Rifampin for latent TB

2/9/2019
More
In this episode, we're joined by Dr. Richard Menzies and Dr. Jonathan Campbell from the McGill Respiratory Epidemiology and Clinical Research Unit to discuss the results of their multi-center RCT comparing 4 months of rifampin to 9 months of isoniazid for the treatment of latent TB. Their findings are outlined in two papers, entitled "Four Months of Rifampin or Nine Months of Isoniazid for Latent TB in Adults" and "Safety and Side Effects of Rifampin Versus Isoniazid in Children" published...

Duration:00:09:57

Episode 3 - Matthew Dankner - Dual MAPK inhibition in a subset of BRAF mutant melanomas

7/11/2018
More
In this episode, we're joined by MD/PhD student Matthew Dankner to discuss his paper "Dual MAPK inhibition is an effective therapeutic strategy for a subset of class II BRAF mutant melanoma" published in the June 2018 issue of Clinical Cancer Research.

Duration:00:08:29

Episode 2 - Devin Abrahami - DPP-4 inhibitors and incidence of IBD among patients with DMII

5/13/2018
More
On this episode we're very grateful to have interviewed PhD candidate Devin Abrahami, the first author of the paper "Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study" published in the March 2018 issue of the British Medical Journal. This paper from the group of Dr. Laurent Azoulay really made a lot of waves in the medical community, achieving an Altmetric score of 320 and still climbing and is a...

Duration:00:15:38

Episode 1 - Paul Savage - A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer

2/24/2018
More
Paul Savage is an MD-PhD student in the lab of Dr. Morag Park at the Goodman Cancer Research Centre in Montreal, Canada. In this episode, we discuss his latest article published in the October 2017 edition of Cell Reports. Using a patient-derived xenograft model to screen triple negative breast cancer (TNBC) tumours for susceptibility to targeted therapies, he and his colleagues identified an exceptional responder to treatment with the epidermal growth factor receptor (EGFR) inhibitor...

Duration:00:08:00